Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026)
Bristol Myers Squibb (CELG-RI) reported Amortization - Intangibles of $437.0 million for Q1 2026, down 47.35% year-over-year from $830.0 million in Q1 2025, and down 47.09% quarter-over-quarter from $826.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 8 years of Amortization - Intangibles data on file, last reported at $437.0 million in Q1 2026.
- Amortization - Intangibles for Q1 2026 came in at $437.0 million, down 47.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 billion (down 60.19% YoY), and the FY2025 annual result was $3.3 billion, down 62.61% from the prior year.
- Amortization - Intangibles eased to $437.0 million in Q1 2026 per CELG-RI's latest filing, from $826.0 million in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $2.4 billion in Q3 2022 and troughed at $437.0 million in Q1 2026.
- A 5-year average of $1.8 billion and a median of $2.3 billion in 2023 frame the typical range for Amortization - Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortization - Intangibles rose 7.04% in 2024, then slumped 65.65% in 2025.
- A 5-year view of Amortization - Intangibles shows it stood at $2.3 billion in 2022, then dropped by 2.77% to $2.3 billion in 2023, then slipped by 25.68% to $1.7 billion in 2024, then plunged by 51.21% to $826.0 million in 2025, then plunged by 47.09% to $437.0 million in 2026.
- Business Quant data shows CELG-RI's Amortization - Intangibles at $437.0 million in Q1 2026, $826.0 million in Q4 2025, and $831.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437.00 Mn |
| Dec 31, 2025 | 826.00 Mn |
| Sep 30, 2025 | 831.00 Mn |
| Jun 30, 2025 | 830.00 Mn |
| Mar 31, 2025 | 830.00 Mn |
| Dec 31, 2024 | 1.69 Bn |
| Sep 30, 2024 | 2.41 Bn |
| Jun 30, 2024 | 2.42 Bn |
| Mar 31, 2024 | 2.36 Bn |
| Dec 31, 2023 | 2.28 Bn |
| Sep 30, 2023 | 2.26 Bn |
| Jun 30, 2023 | 2.26 Bn |
| Mar 31, 2023 | 2.26 Bn |
| Dec 31, 2022 | 2.34 Bn |
| Sep 30, 2022 | 2.42 Bn |
| Jun 30, 2022 | 2.42 Bn |
| Mar 31, 2022 | 2.42 Bn |
| Dec 31, 2021 | 2.42 Bn |
| Sep 30, 2021 | 2.55 Bn |
| Jun 30, 2021 | 2.55 Bn |